The estimated Net Worth of Ventures, Llc Paperboy is at least $15.5 Milione dollars as of 7 May 2009. Ventures Paperboy owns over 287,975 units of Corcept Therapeutics Inc stock worth over $7,454,622 and over the last 17 years Ventures sold CORT stock worth over $8,015,111.
Ventures has made over 18 trades of the Corcept Therapeutics Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently Ventures sold 287,975 units of CORT stock worth $201,583 on 7 May 2009.
The largest trade Ventures's ever made was selling 10,914,507 units of Corcept Therapeutics Inc stock on 6 February 2009 worth over $7,531,010. On average, Ventures trades about 818,637 units every 31 days since 2007. As of 7 May 2009 Ventures still owns at least 209,694 units of Corcept Therapeutics Inc stock.
You can see the complete history of Ventures Paperboy stock trades at the bottom of the page.
Ventures's mailing address filed with the SEC is 1875 K STREET, N.W., SUITE 700, , WASHINGTON, DC, 20006.
Over the last 21 years, insiders at Corcept Therapeutics Inc have traded over $107,318,493 worth of Corcept Therapeutics Inc stock and bought 71,912,273 units worth $127,133,071 . The most active insiders traders include Patrick G Enright, Allen Andersson e Ventures, Llc Paperboy. On average, Corcept Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $8,010,233. The most recent stock trade was executed by William Guyer on 3 September 2024, trading 10,000 units of CORT stock currently worth $216,500.
leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
Corcept Therapeutics Inc executives and other stock owners filed with the SEC include: